{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:34:12Z","timestamp":1792510452924,"version":"4.5.0"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.radonc.2020.11.020","type":"journal-article","created":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T11:27:49Z","timestamp":1606217269000},"page":"269-277","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Idiopathic pulmonary fibrosis: Current knowledge, future perspectives and its importance in radiation oncology"],"prefix":"10.1016","volume":"155","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9084-2599","authenticated-orcid":false,"given":"G\u00f6rkem","family":"T\u00fcrkkan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Willems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizza E.L.","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9my","family":"Mostard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2348-1826","authenticated-orcid":false,"given":"Lennart","family":"Conemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6077-1446","authenticated-orcid":false,"given":"Hester A","family":"Gietema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mitea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0128-3121","authenticated-orcid":false,"given":"St\u00e9phanie","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"De Ruysscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.radonc.2020.11.020_b0005","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1183\/09031936.00185114","article-title":"Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review","volume":"46","author":"Hutchinson","year":"2015","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.radonc.2020.11.020_b0010","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1378\/chest.09-1002","article-title":"Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis","volume":"137","author":"Fern\u00e1ndez P\u00e9rez","year":"2010","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.radonc.2020.11.020_b0015","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S2213-2600(14)70101-8","article-title":"Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001\u201311","volume":"2","author":"Raghu","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.radonc.2020.11.020_b0020","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1183\/13993003.02316-2014","article-title":"Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review","volume":"46","author":"Raghu","year":"2015","journal-title":"Eur Respir J"},{"issue":"8","key":"10.1016\/j.radonc.2020.11.020_b0025","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1513\/AnnalsATS.201807-481OC","article-title":"Idiopathic pulmonary fibrosis and lung cancer. a systematic review and meta-analysis","volume":"16","author":"Brown","year":"2019","journal-title":"Annals ATS"},{"key":"10.1016\/j.radonc.2020.11.020_b0030","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3389\/fonc.2019.00877","article-title":"Radiation-induced lung injury (RILI)","volume":"9","author":"Giuranno","year":"2019","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.radonc.2020.11.020_b0035","doi-asserted-by":"crossref","first-page":"676","DOI":"10.4143\/crt.2014.180","article-title":"Interstitial lung change in pre-radiation therapy computed tomography is a risk factor for severe radiation pneumonitis","volume":"47","author":"Lee","year":"2015","journal-title":"Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.radonc.2020.11.020_b0040","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/JTO.0000000000000359","article-title":"Impact of pretreatment interstitial lung disease on radiation pneumonitis and survival after stereotactic body radiation therapy for lung cancer","volume":"10","author":"Ueki","year":"2015","journal-title":"J Thorac Oncol"},{"issue":"7","key":"10.1016\/j.radonc.2020.11.020_b0045","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1164\/rccm.200602-163OC","article-title":"Incidence and prevalence of idiopathic pulmonary fibrosis","volume":"174","author":"Raghu","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.radonc.2020.11.020_b0050","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2147\/CLEP.S54815","article-title":"Epidemiology of idiopathic pulmonary fibrosis","volume":"5","author":"Ley","year":"2013","journal-title":"Clin Epidemiol."},{"issue":"1","key":"10.1016\/j.radonc.2020.11.020_b0055","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1465-9921-13-64","article-title":"A Newfoundland cohort of familial and sporadic idiopathic pulmonary fibrosis patients: clinical and genetic features","volume":"13","author":"Fernandez","year":"2012","journal-title":"Respir Res"},{"issue":"6","key":"10.1016\/j.radonc.2020.11.020_b0060","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1183\/09031936.00163814","article-title":"The genetic basis of idiopathic pulmonary fibrosis","volume":"45","author":"Kropski","year":"2015","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.radonc.2020.11.020_b0065","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S2213-2600(13)70045-6","article-title":"Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study","volume":"1","author":"Noth","year":"2013","journal-title":"The Lancet Respiratory Medicine"},{"issue":"16","key":"10.1016\/j.radonc.2020.11.020_b0070","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa1013660","article-title":"A Common MUC5B Promoter Polymorphism and Pulmonary Fibrosis","volume":"364","author":"Seibold","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2020.11.020_b0075","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1164\/rccm.201409-1626ED","article-title":"The lung microbiome in idiopathic pulmonary fibrosis. What does it mean and what should we do about it?","volume":"190","author":"Morris","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"21","key":"10.1016\/j.radonc.2020.11.020_b0080","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1001\/jama.2013.5827","article-title":"Association Between the MUC5B Promoter Polymorphism and Survival in Patients With Idiopathic Pulmonary Fibrosis","volume":"309","author":"Peljto","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.radonc.2020.11.020_b0085","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3389\/fmed.2017.00154","article-title":"Genetics in Idiopathic Pulmonary Fibrosis Pathogenesis, Prognosis, and Treatment","volume":"4","author":"Kaur","year":"2017","journal-title":"Front Med (Lausanne)."},{"issue":"19","key":"10.1016\/j.radonc.2020.11.020_b0090","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra1705751","article-title":"Idiopathic Pulmonary Fibrosis","volume":"378","author":"Longo","year":"2018","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.radonc.2020.11.020_b0095","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1164\/rccm.201504-0818OC","article-title":"Idiopathic Pulmonary Fibrosis in United States Automated Claims. Incidence, Prevalence, and Algorithm Validation","volume":"192","author":"Esposito","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.radonc.2020.11.020_b0100","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1177\/1753465810379801","article-title":"The pathogenesis of idiopathic pulmonary fibrosis","volume":"4","author":"Coward","year":"2010","journal-title":"Therapeutic Advances in Respiratory"},{"key":"10.1016\/j.radonc.2020.11.020_b0105","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1378\/chest.125.6.2278","article-title":"Identification of spontaneous feline idiopathic pulmonary fibrosis: morphology and ultrastructural evidence for a type II pneumocyte defect","volume":"125","author":"Williams","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.radonc.2020.11.020_b0110","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.12659\/MSM.902353","article-title":"The Cellular and Molecular Mechanism of Radiation-Induced Lung Injury","volume":"23","author":"Huang","year":"2017","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.radonc.2020.11.020_b0115","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1164\/ajrccm.164.6.2001056","article-title":"Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality","volume":"164","author":"King","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.radonc.2020.11.020_b0120","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/path.2277","article-title":"Cellular and molecular mechanisms of fibrosis","volume":"214","author":"Wynn","year":"2008","journal-title":"J Pathol"},{"key":"10.1016\/j.radonc.2020.11.020_b0125","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nrm2233","article-title":"Cellular senescence: when bad things happen to good cells","volume":"8","author":"Campisi","year":"2007","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.radonc.2020.11.020_b0130","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.ijrobp.2016.07.026","article-title":"Mammalian target of rapamycin inhibition with rapamycin mitigates radiation-induced pulmonary fibrosis in a murine model","volume":"96","author":"Chung","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.11.020_b0135","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02367-2016","article-title":"Senolytic drugs target alveolar epithelial cell function and attenuate experimental lung fibrosis ex vivo","volume":"50","author":"Lehmann","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.radonc.2020.11.020_b0140","doi-asserted-by":"crossref","first-page":"14532","DOI":"10.1038\/ncomms14532","article-title":"Cellular senescence mediates fibrotic pulmonary disease","volume":"8","author":"Schafer","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.radonc.2020.11.020_b0145","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.critrevonc.2018.06.012","article-title":"Ionizing radiation-induced cellular senescence promotes tissue fibrosis after radiotherapy. A review","volume":"129","author":"Nguyen","year":"2018","journal-title":"Crit Rev Oncol Hematol."},{"key":"10.1016\/j.radonc.2020.11.020_b0150","doi-asserted-by":"crossref","first-page":"136","DOI":"10.7326\/0003-4819-134-2-200101160-00015","article-title":"European Respiratory S, American College of Chest P. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy","volume":"134","author":"Selman","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.radonc.2020.11.020_b0155","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature02006","article-title":"Smad-dependent and Smad-independent pathways in TGF-beta family signalling","volume":"425","author":"Derynck","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.radonc.2020.11.020_b0160","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJMra003200","article-title":"Idiopathic pulmonary fibrosis","volume":"345","author":"Gross","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2020.11.020_b0165","first-page":"3119","article-title":"Histological changes after radiation therapy in patients with lung cancer: a prospective study","volume":"34","author":"Karpathiou","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.radonc.2020.11.020_b0170","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ijrobp.2005.01.041","article-title":"Interleukin (IL)-1A and IL-6: applications to the predictive diagnostic testing of radiation pneumonitis","volume":"62","author":"Chen","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.11.020_b0175","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1053\/srao.2002.31360","article-title":"Radiation pneumonitis and early circulatory cytokine markers","volume":"12","author":"Chen","year":"2002","journal-title":"Semin Radiat Oncol."},{"key":"10.1016\/j.radonc.2020.11.020_b0180","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2214\/AJR.15.15627","article-title":"The value of a multidisciplinary approach to the diagnosis of usual interstitial pneumonitis and idiopathic pulmonary fibrosis: radiology, pathology, and clinical correlation","volume":"206","author":"Chung","year":"2016","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.radonc.2020.11.020_b0185","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.radonc.2020.11.020_b0190","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1148\/rg.2019180061","article-title":"Recognizing radiation therapy-related complications in the chest","volume":"39","author":"Benveniste","year":"2019","journal-title":"Radiographics."},{"key":"10.1016\/j.radonc.2020.11.020_b0195","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00259-013-2514-8","article-title":"Areas of normal pulmonary parenchyma on HRCT exhibit increased FDG PET signal in IPF patients","volume":"41","author":"Win","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.radonc.2020.11.020_b0200","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1183\/09059180.00002114","article-title":"Staging of idiopathic pulmonary fibrosis: past, present and future","volume":"23","author":"Kolb","year":"2014","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.radonc.2020.11.020_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2020.01.006","article-title":"Circulating lung biomarkers in idiopathic lung fibrosis and interstitial lung diseases associated with connective tissue diseases: Where do we stand?","author":"Elhai","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.radonc.2020.11.020_b0210","doi-asserted-by":"crossref","first-page":"4759040","DOI":"10.1155\/2016\/4759040","article-title":"Comparative study of circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as disease markers of idiopathic pulmonary fibrosis","volume":"2016","author":"Hamai","year":"2016","journal-title":"Dis Markers"},{"key":"10.1016\/j.radonc.2020.11.020_b0215","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1164\/rccm.201006-0894CI","article-title":"Clinical course and prediction of survival in idiopathic pulmonary fibrosis","volume":"183","author":"Ley","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.radonc.2020.11.020_b0220","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.radonc.2020.11.020_b0225","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1183\/09031936.00159709","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome","volume":"37","author":"Song","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.radonc.2020.11.020_b0230","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1164\/rccm.200211-1311OC","article-title":"Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis","volume":"168","author":"Collard","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.radonc.2020.11.020_b0235","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1183\/09031936.00155108","article-title":"Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis","volume":"35","author":"Zappala","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.radonc.2020.11.020_b0240","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/thorax.58.2.143","article-title":"Radiological versus histological diagnosis in UIP and NSIP: survival implications","volume":"58","author":"Flaherty","year":"2003","journal-title":"Thorax"},{"key":"10.1016\/j.radonc.2020.11.020_b0245","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1164\/rccm.200611-1696OC","article-title":"Computed tomography findings in pathological usual interstitial pneumonia: relationship to survival","volume":"177","author":"Sumikawa","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.radonc.2020.11.020_b0250","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.2967\/jnumed.115.163360","article-title":"Prognostic value of dual-time-point 18F-FDG PET for idiopathic pulmonary fibrosis","volume":"56","author":"Umeda","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/j.radonc.2020.11.020_b0255","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12931-017-0556-3","article-title":"[(18)F]FDG PET\/CT predicts progression-free survival in patients with idiopathic pulmonary fibrosis","volume":"18","author":"Justet","year":"2017","journal-title":"Respir Res"},{"key":"10.1016\/j.radonc.2020.11.020_b0260","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.rmed.2010.09.012","article-title":"Serum and BALF YKL-40 levels are predictors of survival in idiopathic pulmonary fibrosis","volume":"105","author":"Korthagen","year":"2011","journal-title":"Respir Med"},{"key":"10.1016\/j.radonc.2020.11.020_b0265","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1164\/rccm.201309-1592OC","article-title":"C-X-C motif chemokine 13 (CXCL13) is a prognostic biomarker of idiopathic pulmonary fibrosis","volume":"189","author":"Vuga","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.radonc.2020.11.020_b0270","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1136\/thx.2003.009860","article-title":"Angiogenic cytokines in patients with idiopathic interstitial pneumonia","volume":"59","author":"Simler","year":"2004","journal-title":"Thorax"},{"key":"10.1016\/j.radonc.2020.11.020_b0275","article-title":"Impact of serum SP-A and SP-D levels on comparison and prognosis of idiopathic pulmonary fibrosis: A systematic review and meta-analysis","volume":"96","author":"Wang","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.radonc.2020.11.020_b0280","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/resp.12920","article-title":"Validation of the prognostic value of MMP-7 in idiopathic pulmonary fibrosis","volume":"22","author":"Tzouvelekis","year":"2017","journal-title":"Respirology"},{"key":"10.1016\/j.radonc.2020.11.020_b0285","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1177\/107327480801500206","article-title":"The use of blood biomarkers to predict radiation lung toxicity: a potential strategy to individualize thoracic radiation therapy","volume":"15","author":"Kong","year":"2008","journal-title":"Cancer Control"},{"key":"10.1016\/j.radonc.2020.11.020_b0290","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S0360-3016(98)00154-0","article-title":"Plasma transforming growth factor beta1 as a predictor of radiation pneumonitis","volume":"41","author":"Anscher","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.11.020_b0295","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0169-5002(01)00215-X","article-title":"Serum levels of KL-6 are useful biomarkers for severe radiation pneumonitis","volume":"34","author":"Goto","year":"2001","journal-title":"Lung Cancer"},{"key":"10.1016\/j.radonc.2020.11.020_b0300","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","article-title":"An official ATS\/ERS\/JRS\/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline","volume":"192","author":"Raghu","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.radonc.2020.11.020_b0305","first-page":"89","article-title":"Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis","volume":"10","author":"Inomata","year":"2015","journal-title":"Core Evid."},{"key":"10.1016\/j.radonc.2020.11.020_b0310","article-title":"Pirfenidone for idiopathic pulmonary fibrosis: A systematic review and meta-analysis","volume":"10","author":"Aravena","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.radonc.2020.11.020_b0315","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2020.11.020_b0320","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials","volume":"377","author":"Noble","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2020.11.020_b0325","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1103690","article-title":"Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis","volume":"365","author":"Richeldi","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2020.11.020_b0330","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.rmed.2016.02.001","article-title":"Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS((R)) trials","volume":"113","author":"Richeldi","year":"2016","journal-title":"Respir Med"},{"key":"10.1016\/j.radonc.2020.11.020_b0335","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1164\/rccm.201706-1301OC","article-title":"Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis. Results of the injourney trial","volume":"197","author":"Vancheri","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.radonc.2020.11.020_b0340","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1084\/jem.20041393","article-title":"Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis","volume":"201","author":"Abdollahi","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.radonc.2020.11.020_b0345","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1158\/1078-0432.CCR-11-2855","article-title":"LY2109761 attenuates radiation-induced pulmonary murine fibrosis via reversal of TGF-beta and BMP-associated proinflammatory and proangiogenic signals","volume":"18","author":"Flechsig","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2020.11.020_b0350","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1123366","article-title":"Combined inhibition of TGFbeta and PDGF signaling attenuates radiation-induced pulmonary fibrosis","volume":"5","author":"Dadrich","year":"2016","journal-title":"Oncoimmunology."},{"key":"10.1016\/j.radonc.2020.11.020_b0355","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw339","article-title":"Effects of CTGF blockade on attenuation and reversal of radiation-induced pulmonary fibrosis","volume":"109","author":"Bickelhaupt","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.radonc.2020.11.020_b0360","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.tranon.2018.09.009","article-title":"Advances in molecular mechanisms and treatment of radiation-induced pulmonary fibrosis","volume":"12","author":"Chen","year":"2019","journal-title":"Transl Oncol"},{"key":"10.1016\/j.radonc.2020.11.020_b0365","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.2174\/1389450111009011386","article-title":"Treatment for radiation-induced pulmonary late effects: spoiled for choice or looking in the wrong direction?","volume":"11","author":"Williams","year":"2010","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.radonc.2020.11.020_b0370","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ijrobp.2012.04.043","article-title":"Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis","volume":"85","author":"Palma","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.11.020_b0375","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13014-019-1221-4","article-title":"Preliminary result of definitive radiotherapy in patients with non-small cell lung cancer who have underlying idiopathic pulmonary fibrosis: comparison between X-ray and proton therapy","volume":"14","author":"Kim","year":"2019","journal-title":"Radiat Oncol."},{"key":"10.1016\/j.radonc.2020.11.020_b0380","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13014-016-0637-3","article-title":"The clinical results of proton beam therapy in patients with idiopathic pulmonary fibrosis: a single center experience","volume":"11","author":"Ono","year":"2016","journal-title":"Radiat Oncol."},{"key":"10.1016\/j.radonc.2020.11.020_b0385","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1007\/s11604-008-0261-8","article-title":"Acute exacerbation of subclinical idiopathic pulmonary fibrosis triggered by hypofractionated stereotactic body radiotherapy in a patient with primary lung cancer and slightly focal honeycombing","volume":"26","author":"Takeda","year":"2008","journal-title":"Radiat Med."},{"key":"10.1016\/j.radonc.2020.11.020_b0390","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1440-1843.2009.01666.x","article-title":"Clinical characteristics of acute respiratory deterioration in pulmonary fibrosis associated with lung cancer following anti-cancer therapy","volume":"15","author":"Isobe","year":"2010","journal-title":"Respirology"},{"key":"10.1016\/j.radonc.2020.11.020_b0395","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.ijrobp.2009.06.091","article-title":"Radiation dose-volume effects in the lung","volume":"76","author":"Marks","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.11.020_b0400","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1093\/jjco\/hyz016","article-title":"Chemoradiotherapy for locally advanced lung cancer patients with interstitial lung abnormalities","volume":"49","author":"Higo","year":"2019","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.radonc.2020.11.020_b0405","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2017.06.003","article-title":"European Organization for Research and Treatment of Cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer","volume":"124","author":"De Ruysscher","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.11.020_b0410","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1748-717X-5-32","article-title":"Prescreening based on the presence of CT-scan abnormalities and biomarkers (KL-6 and SP-D) may reduce severe radiation pneumonitis after stereotactic radiotherapy","volume":"5","author":"Yamashita","year":"2010","journal-title":"Radiat Oncol."},{"key":"10.1016\/j.radonc.2020.11.020_b0415","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.lungcan.2013.08.024","article-title":"Stereotactic body radiotherapy for lung tumors in patients with subclinical interstitial lung disease: the potential risk of extensive radiation pneumonitis","volume":"82","author":"Yamaguchi","year":"2013","journal-title":"Lung Cancer."},{"key":"10.1016\/j.radonc.2020.11.020_b0420","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.ijrobp.2017.03.010","article-title":"Treatment-related toxicity in patients with early-stage non-small cell lung cancer and coexisting interstitial lung disease: a systematic review","volume":"98","author":"Chen","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.11.020_b0425","first-page":"141","article-title":"Proton beam therapy in non-small cell lung cancer: state of the art","volume":"8","author":"Harada","year":"2017","journal-title":"Lung Cancer (Auckl)."},{"key":"10.1016\/j.radonc.2020.11.020_b0430","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/jjco\/hys115","article-title":"A case of acute exacerbation of idiopathic pulmonary fibrosis after proton beam therapy for non-small cell lung cancer","volume":"42","author":"Nagano","year":"2012","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.radonc.2020.11.020_b0435","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.7150\/jca.24936","article-title":"Impact of interstitial lung disease classification on the development of acute exacerbation of interstitial lung disease and prognosis in patients with stage III non-small-cell lung cancer and interstitial lung disease treated with chemoradiotherapy","volume":"9","author":"Kobayashi","year":"2018","journal-title":"J Cancer."},{"key":"10.1016\/j.radonc.2020.11.020_b0440","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.radonc.2017.07.014","article-title":"Nintedanib reduces radiation-induced microscopic lung fibrosis but this cannot be monitored by CT imaging: A preclinical study with a high precision image-guided irradiator","volume":"124","author":"De Ruysscher","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.11.020_b0445","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1667\/RR15017.1","article-title":"Antifibrotic agent pirfenidone protects against development of radiation-induced pulmonary fibrosis in a murine model","volume":"190","author":"Qin","year":"2018","journal-title":"Radiat Res"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814020311907?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814020311907?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:16:01Z","timestamp":1759122961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814020311907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":89,"alternative-id":["S0167814020311907"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2020.11.020","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Idiopathic pulmonary fibrosis: Current knowledge, future perspectives and its importance in radiation oncology","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2020.11.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}